The $100B Weight-Loss Market: Accelerating from Single-Point Breakthroughs to Ecosystem Building — Roundtable Session 10 of China Innovation Healthcare Asset Salon
In the past two years, the weight loss sector has exhibited a dual boom in both pharmaceuticals and medical devices. GLP-1 drugs have ignited a global market frenzy, with the global market size exceeding $50 billion in 2024 and projected to surpass $60 billion in 2025. Chinese companies such as CSPC Pharmaceutical Group and Hansoh Pharma have broken through via business development (BD) deals valued at over $2 billion. Meanwhile, gastric bypass stent systems have been included in the Guidelines for Diagnosis and Treatment of Obesity (2024 Edition). Innovative domestic medical devices have received FDA Breakthrough Device designation, and combination products such as gastric space-occupying weight loss capsules have been submitted for marketing approval and secured licensing agreements worth hundreds of millions of yuan. Technology transactions and joint development have become the predominant collaboration models in the pharmaceutical and medical device sectors.
Against this backdrop, the transaction session of “China’s Innovative Healthcare Asset Lounge,” hosted by VCBeat, will take place at 15:00 on Tuesday, December 16.Roundtable Discussion, Episode 10, featuringBi Cheng, Partner at Wenzhou Investment; Chen Linfeng, Strategic Financing Director at Tangji Medical; Fu Quan, Partner at Langmafeng Venture Capital; Han Dong, Head of Business Development at Junshengtai PharmaceuticalsFour guests centered aroundThe Multi-Billion-Dollar Weight Loss Market: Sustained Surge, from Breakthroughs in Single Areas to Ecosystem Building!ChiefThrough in-depth thematic discussions, we provide buy-side investors with actionable trading frameworks and insights into frontier sector allocation, establishing a “strategic think tank” for healthcare innovation asset transactions. This initiative empowers the buy side to efficiently capture high-quality asset opportunities, bridging China’s healthcare innovation assets with global buyers.
Moderator: Bi Cheng
Partner, Wenzhou Investment
Bachelor's and Master's degrees in Pharmacy from Peking University,Previously served as the Technical Director at Shanghai Modern Pharmaceutical Co., Ltd.Subsequently served as the Head of Pharmaceutical Research at GTJA Innovation Investment and GaoTeJia Investment.Currently a Partner at Shanghai Wenzhou Investment Management Co., Ltd.,Investment Cases: Minovate, Puguang Biotech, ImmuneOnco, Phagocytosis Era, Deepwise Medical.
Guest: Chen Linfeng
Director of Strategic Financing, Tangji Medical
Oversee the company’s overall investment and financing operations, with responsibilities spanning core areas such as financing planning, capital operations, and investment strategy. Previously served in the Strategic Investment Department of Wuchan Zhongda Group, a Fortune 500 company, where he specialized in industrial investment, fund-of-funds (FOF), and equity investment. He led the management of multiple industrial funds and FOF products, accumulating substantial hands-on experience in corporate investment. Leveraging deep insights into the healthcare industry, he accurately identifies industrial development trends and capital operation dynamics, providing professional support for the effective implementation of Tangji Medical’s investment and financing strategies.
Guest: Fu Quan
Partner at Longma Peak Ventures
Major in Biochemistry and Molecular Biology at Zhejiang University. Focused on investments in the healthcare and life sciences sectors, with over 12 years of experience in investment and consulting. Previously worked at Accenture Strategy, Cathay Capital, and QiaoYing Capital. Led or deeply participated in investment cases including Vitaeris, Wentai Pharmaceuticals, OrangeSail Pharma, CARsgen Therapeutics (02171.HK), Abcuro, Totient, Anxuyuan, LinkMed Pharmaceuticals, and Jiayin Biologics. Also responsible for the management of multiple portfolio companies, including Changfeng Pharm (02652.HK), Bette Pharma (688759.SH), Huahao Zhongtian (02563.HK), Sinotau Pharmaceuticals, and TianGuangShi.
Guest: Han Dong
Head of Business Development, Junshengtai Pharmaceuticals
Dr. Han Dong holds a Bachelor of Pharmacy degree from the School of Pharmaceutical Sciences at Peking University and a Ph.D. in Chemical Biology, with over twenty years of research and professional experience in the pharmaceutical industry. Prior to joining Junshintai, he served as Senior Director of Business Development at Neufus Therapeutics, a biopharmaceutical company, where he was responsible for international product expansion and launch readiness. Previously, he worked at several multinational pharmaceutical companies, including Merck Serono, Bayer, Novartis, and GlaxoSmithKline, as well as at Sinolink Consultants, where he held roles encompassing new drug R&D, market research, market access, corporate strategy, and new product commercialization.
China Innovative Healthcare Assets Reception Room - Trading Roundtable
“China’s Innovative Healthcare Asset Lounge” is an online live-streaming program by VCBeat, positioned around the core mission of “connecting China’s innovative healthcare assets with global buyers.” It focuses on high-quality asset transactions in fields such as innovative drugs, high-end medical devices, and digital health, aiming to build a professional platform for “showcase, exchange, and matchmaking” tailored to strategic, financial, and industrial buyers. With the goal of “unlocking the value of China’s innovative assets and facilitating efficient transactions,” the program helps buyer groups capture opportunities in premium assets through precise supply-demand matching, analysis of transaction logic, and sharing of practical experience, while also promoting the conversion and retention of local innovative assets, thereby supporting the ecosystem development of the Global Life and Health Innovative Asset Buyers Alliance.
“Deal Roundtable,” a sub-column of China’s Innovation Healthcare Asset Lounge, focuses on the strategies, trends, and regulations governing transactions in innovative healthcare assets. Adopting a “buyer-centric perspective,” it invites members of the Buyer Alliance, seasoned investors, and experts from law firms and investment banks to engage in dialogues around hot-button issues and pain points in deal-making. By combining “benchmark case studies with strategic insights,” the column provides buyers with actionable transaction logic and references for positioning in cutting-edge sectors, establishing itself as a “strategic think tank” for innovative healthcare asset transactions and empowering buyers to efficiently capture high-quality deal opportunities.
Scan the QR code to reserve your spot for the live stream.